Why Array Technologies, Inc. (ARRY) is a Top Momentum Stock for the Long-Term

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, aiding investors in selecting stocks with high potential for market outperformance [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on value, growth, and momentum characteristics, with higher scores indicating better chances of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks with upward or downward price trends, utilizing one-week price changes and monthly earnings estimate changes to identify optimal buying times [5] VGM Score - Combines the three Style Scores to highlight stocks with attractive value, strong growth forecasts, and promising momentum, serving as a key indicator alongside the Zacks Rank [6] Zacks Rank Integration - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9] Company Spotlight: Array Technologies, Inc. (ARRY) - Array Technologies is a biopharmaceutical company focused on targeted small molecule drugs for cancer treatment, with a marketed therapy for melanoma [11] - ARRY holds a Zacks Rank of 2 (Buy) and a VGM Score of A, with a Momentum Style Score of B, reflecting a 10.8% increase in shares over the past four weeks [12] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate increase of $0.03 to $0.66 per share highlight ARRY's strong performance potential [12][13]